Will the Use of Respiratory Quotient ''RQ'' Improve Treatment Outcomes for Intensive Care Unit (ICU) Patients?

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorPoznan University of Medical Sciences

About this trial

Introduction and assumptions of the research project:

Patients treated in intensive care units (ICUs) require comprehensive treatment. Nutrition is an important and integral part of this therapy. Both insufficient and excessive calorie intake are associated with poorer prognosis and increased mortality in ICU patients. Furthermore, the caloric requirements of patients in life-threatening conditions in the ICU are characterized by periods of hypo- and hypermetabolism, which, if nutrition is not optimized, expose patients to overfeeding or underfeeding. Therefore, monitoring resting energy expenditure (REE) using indirect calorimetry has become the "gold standard" in the ICU. Previous methods based on mathematical formulas for calculating REE were characterized by insufficient correlation with actual demand. Indirect calorimetry uses measured exhaled carbon dioxide and the concentration of oxygen administered. Then, taking into account patient-dependent parameters such as gender, height, and weight, it indirectly calculates energy expenditure, which corresponds to caloric demand. By dividing the volume of CO2 released by the volume of O2 absorbed, investigators can obtain the respiratory quotient (RQ). This quotient is related to the type of diet and is, for example, 0.7 for fats, 0.8 for proteins, and 1.0 for carbohydrates. Its value also changes with nutritional status. High values may suggest an excessive energy supply (relative to demand), while low values may indicate a calorie deficit. Some authors suggest that the RQ ratio could potentially be used to further optimize nutritional status. Currently, however, due to insufficient research, it is mainly used in clinical practice to assess the accuracy of recording and monitoring calorimetry. This study, is trying to assess the usefulness of RQ for optimizing nutrition in patients treated in the ICU.

Methodology:

Study group:

This will be a randomized study with a study group and a control group in patients treated in the ICU. All patients participating in the study are patients who, at the time of qualification, are mechanically ventilated and treated in the ICU. These will be patients of both sexes, aged 18-85 years. The control group will be fed under the supervision of indirect calorimetry and REE, in accordance with current ICU nutrition guidelines. In the study group, nutritional preparations will be additionally systematized and selected for each patient depending on their RQ value, and caloric requirements will be controlled by indirect calorimetry and REE, as in the control group. Regular assessments of albumin, total protein, total cholesterol, LDL, HDL, iron, glycemia, Na+, K+, and triglycerides will be conducted, collected along with the routine test package. In addition, typical endpoints for patients treated in the ICU will be assessed, such as length of stay in the ICU, length of mechanical ventilation, number of days without a ventilator, 28-day survival, and survival to hospital discharge.

Expected duration of the study: October 2024 to October 2026 (2 years) Conditions for inclusion in the study: patients \> 18 years of age, treated in the ICU, mechanically ventilated, covered by universal health insurance Conditions for exclusion from the study: ECMO therapy, the need for mechanical ventilation with an oxygen concentration in the breathing mixture FiO2 \> 60%, patients breathing independently without the aid of a ventilator, critically ill patients who are not expected to survive the next 48 hours, pregnant women, patients \< 18 years of age or \> 85 years of age

Reasons for discontinuing the study:

1. if, during the course of the study, there are clear indications that one of the groups will experience or worsen final outcomes such as mortality, 28-day mortality, length of stay in the ICU - which would suggest a clear advantage of one of the chosen strategies, along with an increase in the number of patients included in the study, a regular analysis of the current effects of both strategies will be conducted, 2. the patient develops hypersensitivity/intolerance to nutritional preparations, with no possibility of switching to another preparation used in the study,

Expected results and their planned subsequent use:

Patients from the control group, should achieve faster stabilization of nutritional parameters and fewer episodes of underfeeding and overfeeding. This should translate into improved endpoints such as mortality, length of stay in the ICU, and shorter mechanical ventilation time. In addition, the systematization and algorithms for the use of nutritional products developed during the study can be further used in department of the study and other departments around the world.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patient treated in the ICU

mechanically ventilated

covered by universal health insurance

Disqualifiers

ECMO therapy

mechanical ventilation with an oxygen concentration in the breathing mixture FiO2 > 60%

breathing independently without the aid of a ventilator

critically ill patients who are not expected to survive the next 48 hours

Trial design

Design model

Parallel

Treatments tested in this trial

  • RQ guided nutrition

    Dietary supplement

    In the study group, nutritional preparations will be additionally systematized and selected for each patient depending on their RQ value, and caloric requirements will be controlled by indirect calorimetry and REE, as in the control group.

  • Standard Treatment (Guideline-Based)

    Dietary supplement

    Standard treatment according to ESPEN guidelines.

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: ControlActive comparator 1 intervention
Group B: Research groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

28-day survival rate

If the patients survives 28 days after initial admission to ICU and inclusion in the study.

Time frame
28 days after initial admission to ICU and inclusion in the study.
2

Survival rate until hospital discharge.

: If the patients survives until hospital discharge after initial admission to ICU and inclusion in the study.

Time frame
From initial admission to ICU and inclusion in the study to hospital discharge, assessed up to 120 days from the randomisation.
3

Survival rate in an ICU.

If the patients survives until discharge from an ICU after initial admission to ICU and inclusion in the study.

Time frame
From initial admission to the ICU and inclusion in the study to discharge from the ICU, assessed up to 120 days from the randomisation.

Secondary outcomes

1

Length of stay in the ICU.

Measured total length of stay in the ICU until discharge from hospital.

Time frame
From initial admission to the ICU and inclusion in the study to discharge from the hospital or death, assessed up to 120 days from the randomisation.
2

Ventilator free days

Number of days without mechanical ventilation during ICU stay.

Time frame
From initial admission to the ICU and inclusion in the study to discharge from the ICU, assessed up to 120 days from the randomisation.
3

Ventilator-associated pneumonia (VAP)

Occurrence of VAP during ICU stay

Time frame
From initial admission to the ICU and inclusion in the study to discharge from the ICU, monitored up to 120 days from the randomisation.

Other outcomes

1

Sequential Organ Failure Assessment (SOFA) score

Measurement of Sequential Organ Failure Assessment (SOFA) score , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 24 points, where 0 represents the lowest predicted mortality and 24 represents the highest predicted mortality.

Time frame
Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
2

Acute Physiology and Chronic Health Evaluation II (APACHE II) score

Measurement of Acute Physiology and Chronic Health Evaluation II (APACHE II) score , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 71 points, where 0 represents the lowest predicted mortality and 71 represents the highest predicted mortality.

Time frame
Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
3

Simplified Acute Physiology Score II (SAPS II)

Measurement of Simplified Acute Physiology Score II (SAPS II) , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 163 points, where 0 represents the lowest predicted mortality and 163 represents the highest predicted mortality.

Time frame
Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.